Patient Discovery
Oncology-focused platform for patient needs management, SDoH assessment, patient engagement, and reimbursement workflows.
Website: https://www.patientdiscovery.com/
PUBLIC
| Company | Patient Discovery Solutions, Inc. |
| Tagline | Oncology-focused platform for patient needs management, SDoH assessment, patient engagement, and reimbursement workflows. |
| Headquarters | Boston, United States |
| Founded | 2016 |
| Stage | Series A |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Seed (total disclosed ~$8,350,000) |
Links
PUBLIC
- Website: https://www.patientdiscovery.com/
- LinkedIn: https://www.linkedin.com/company/patient-discovery
Executive Summary
PUBLIC Patient Discovery is a Boston-area healthtech company that has built a software platform to help oncology practices identify, manage, and bill for the non-clinical needs of cancer patients, a wedge into a market increasingly incentivized by Medicare reimbursement changes [Patient Discovery, retrieved 2024]. Founded in 2016, the company targets a specific operational pain point: capturing revenue for the extensive support work that falls outside traditional clinical care, such as addressing social determinants of health (SDoH) and providing principal illness navigation (PIN) [EIN Presswire, Oct 2024]. Its product, Companion by Patient Discovery™, centralizes this workflow, aiming to streamline operations and generate reimbursable claims without adding administrative burden for care teams [Patient Discovery, retrieved 2024].
The founding team brings a blend of healthcare and enterprise software experience. CEO Norm Shore and CSO Shelby Chamberlain co-founded the company with Adam Sodowick, who previously founded and sold compliance software company True Office to NYSE [Forbes, 2014]. The board includes Sandra Fenwick, the former CEO of Boston Children's Hospital, lending significant healthcare executive credibility [PR Newswire, 2022]. Patient Discovery has raised approximately $8.35 million across several rounds, including a $3.6 million seed in 2017 and a $2 million Series A in April 2025, with backing from investors like Hard Yaka [PitchBook, retrieved 2024]. The business model is SaaS, targeting oncology practices with a value proposition tied directly to reimbursement optimization.
Over the next 12-18 months, the key monitorables are the scale of commercial deployment beyond early references like Nebraska Cancer Specialists and the company's ability to capitalize on recent CMS fee schedule updates that increased reimbursement for PIN services [Patient Discovery, retrieved 2024]. The lack of broad, named-publisher news coverage suggests the company is still in a phase of building direct customer traction rather than achieving widespread market recognition. Data Accuracy: YELLOW -- Core company facts are confirmed by its website and investor profiles, but funding totals and headcount figures show discrepancies across sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Seed (total disclosed ~$8,350,000) |
Company Overview
PUBLIC
Patient Discovery Solutions, Inc. was founded in 2016 in Boston, Massachusetts, with a mission to integrate patient-reported life experiences into clinical decision-making [Patient Discovery, retrieved 2024]. The founding team, comprising Norm Shore (CEO), Shelby Chamberlain (CSO), and Adam Sodowick (Executive Director, Practice Solutions), built the company to address the operational and financial challenges oncology practices face in managing non-clinical patient needs [Patient Discovery, retrieved 2024]. The company's core thesis is that by systematically identifying and addressing social determinants of health (SDoH) and other barriers to care, providers can improve outcomes while unlocking new, reimbursable revenue streams.
Key operational milestones trace a path from initial concept to a focused commercial offering. After a $3.6 million seed round in late 2017, the company developed its platform [PitchBook, retrieved 2024]. A significant inflection point came in 2022 with the appointment of Sandra Fenwick, the former CEO of Boston Children's Hospital, to its board of directors, adding substantial healthcare leadership credibility [PR Newswire, 2022]. The company publicly launched its revenue cycle management solution for CMS-billable services in October 2024, a move timed to capitalize on evolving Medicare reimbursement policies [EIN Presswire, Oct 2024]. Its most recent funding event was a $2 million Series A round in April 2025 [PitchBook, retrieved 2024].
The company's headcount is reported in a range consistent with an early commercial-stage venture. Public sources estimate the team size between 11 and 50 employees, with more specific data points clustering around 18 to 22 staff [ZoomInfo, retrieved 2026] [LeadIQ, May 2026] [ContactOut, retrieved 2026]. This scale suggests a focus on product development, sales, and implementation support for a targeted oncology market.
Data Accuracy: YELLOW -- Core founding and funding dates are confirmed by PitchBook and the company website; headcount figures vary across sources.
Product and Technology
MIXED Patient Discovery's core offering is Companion by Patient Discovery™, a software platform designed to integrate patient needs assessment and care coordination directly into the revenue cycle of oncology practices [Patient Discovery, retrieved 2024]. The product's primary function is to operationalize and monetize the identification of non-clinical barriers to care, such as transportation, food insecurity, or financial stress, which are categorized as Social Determinants of Health (SDoH) [Patient Discovery, retrieved 2024]. By embedding these workflows into the electronic medical record (EMR), the company claims to centralize patient needs management for clinical and non-clinical staff while generating billing-ready reports for services that qualify for CMS reimbursement, specifically Principal Illness Navigation (PIN), Community Health Integration (CHI), and SDoH risk assessment [EIN Presswire, Oct 2024].
The platform's architecture appears to be built around three interconnected modules. Patient engagement. The system provides a patient-facing interface for SDoH risk assessment and education on topics like clinical trials, with the intent of surfacing needs directly within the clinician's EMR view [Patient Discovery, retrieved 2024]. Care coordination. It then facilitates automated referrals and task routing for the care team to address identified needs [Patient Discovery, retrieved 2024]. Revenue cycle management. Finally, it captures all related activity time and documentation to generate claims for the reimbursable CMS codes, aiming to turn supportive care into a revenue stream [Patient Discovery, retrieved 2024]. A key implementation claim is that a practice can be live and producing billable claims within 90 days [Patient Discovery, retrieved 2024].
The technology stack is not explicitly detailed in public materials. Inferences from team backgrounds and the product's described integration points suggest a cloud-based SaaS architecture with API-level connectivity to major EMR systems, a requirement for the 'no extra logins' EMR embedding feature [Patient Discovery, retrieved 2024]. The presence of a Chief Technology Officer with a background in enterprise health platforms like Accolade and H1 supports the inference of a system built for healthcare-grade security, compliance, and interoperability [The Org, retrieved 2026].
Data Accuracy: YELLOW -- Product claims are consistent across the company's website and a press release. Technical stack details are inferred from team composition and product requirements.
Market Research
PUBLIC
The market for oncology-focused patient management software is being reshaped by a fundamental shift in healthcare reimbursement, moving from fee-for-service to value-based models that reward holistic patient support. Patient Discovery's platform targets a specific intersection of this trend: the operationalization of Social Determinants of Health (SDoH) screening and Principal Illness Navigation (PIN) services for cancer care, which are now reimbursable under Medicare.
Quantifying the total addressable market for this niche is challenging due to its novelty. The company's own materials cite an internal analysis suggesting a typical five-physician oncology practice could generate an estimated $1.16 million in total reimbursement using its platform [Patient Discovery, retrieved 2024]. While this is a company-provided projection, it points to the substantial per-practice revenue potential that drives the value proposition. A broader, analogous market sizing comes from the Centers for Medicare & Medicaid Services (CMS), which implemented new billing codes for PIN services in 2024 and announced an 11% increase in reimbursement rates for these codes in the 2026 Medicare Physician Fee Schedule [Patient Discovery, retrieved 2024]. This regulatory change creates a direct, quantifiable financial incentive for oncology practices to adopt tools that can systematically capture and bill for this work.
Several demand drivers underpin this market segment. The persistent focus on health equity, cited by 89% of healthcare executives as a core business priority, is pushing systems to formalize SDoH interventions [Patient Discovery, retrieved 2024]. In oncology specifically, the complexity of treatment regimens and the profound impact of non-clinical factors like transportation, food security, and financial toxicity make comprehensive patient navigation not just a clinical imperative but a financial one. The primary tailwind is regulatory: CMS's creation and expansion of reimbursement pathways for SDoH and chronic care management services transforms these activities from cost centers to revenue opportunities. This policy shift is pulling software solutions into a space previously dominated by manual, grant-funded, or volunteer-staffed programs.
Key adjacent markets include broader revenue cycle management (RCM) software, valued in the tens of billions, and the electronic health record (EHR) market, where giants like Epic and Cerner dominate. Patient Discovery's wedge is not to replace these systems but to specialize in the coding and workflow for a specific, newly reimbursable service line (PIN/SDoH) within oncology, a high-acuity specialty with complex patient needs. Substitute markets are less about software and more about alternative methods for delivering these services, such as hiring additional in-house navigators or outsourcing to specialty benefit managers, though these lack the integrated workflow and automated billing capture the platform promises.
The regulatory environment is both the primary catalyst and a source of ongoing risk. While CMS has established the codes, reimbursement rates and coverage policies are subject to annual review and political influence. Furthermore, successful billing requires strict adherence to documentation and time-tracking requirements, making software that enforces compliance inherently valuable. Macro forces, including provider burnout and staffing shortages, increase the appeal of any solution that promises to streamline complex workflows without adding administrative burden, as the company claims its platform does [Patient Discovery, retrieved 2024].
| Metric | Value |
|---|---|
| PIN Reimbursement per 5-MD Practice | 1.16 $M (estimated) |
| Medicare PIN Rate Increase (2026) | 11 % |
The available figures, though limited, illustrate the core market mechanics: high potential value per practice driven by specific, growing reimbursement codes. The lack of independent, third-party market sizing reports for this precise niche is notable and reflects its emergent status.
Data Accuracy: YELLOW -- Market sizing is based on company-provided estimates and public CMS policy announcements. The 11% rate increase is a published regulatory fact, while the per-practice reimbursement projection is an unverified company analysis.
Competitive Landscape
MIXED Patient Discovery competes not by building a better EMR, but by creating a billing and workflow layer on top of it, specifically for the complex, non-clinical needs of oncology patients.
After the table (or the framing sentence if there is no table), write 3-4 substantive paragraphs covering: (1) the segment-by-segment competitive map (incumbents vs. challengers vs. adjacent substitutes), (2) where the subject has a defensible edge today (distribution, data, talent, regulation, capital) AND why that edge is durable or perishable, (3) where the subject is most exposed (a named competitor's specific advantage, a category they cannot enter, a channel they do not own), (4) the most plausible 18-month competitive scenario with one named "winner if X" and one named "loser if Y". Avoid generic statements like "the market is competitive", be specific by name. Label MIXED. End with accuracy score.
The competitive environment for Patient Discovery is fragmented across several distinct segments. The company's primary competitive set consists of oncology-specific care coordination platforms, such as Thyme Care and Jasper Health, which also focus on patient navigation and support but may not emphasize the revenue cycle management component as centrally [Patient Discovery, retrieved 2024]. A second segment includes broad SDoH and social needs screening platforms like Unite Us and NowPow, which excel at community resource referral but are typically deployed across health systems generally, not fine-tuned for the specific billing codes and clinical workflows of oncology [Patient Discovery, retrieved 2024]. The most significant adjacent substitutes are large electronic health record (EHR) vendors like Epic and Cerner. These incumbents hold the foundational patient record and could theoretically build or acquire similar functionality, though their development cycles for niche oncology billing workflows are often slower [Patient Discovery, retrieved 2024]. Finally, a category of general practice management and RCM software serves as a partial substitute, handling billing but lacking the integrated patient engagement and SDoH assessment layers.
Patient Discovery's current edge appears to be its regulatory and reimbursement specialization. The platform is explicitly built to capture CMS billing for Social Determinants of Health (SDoH), Community Health Integration (CHI), and Principal Illness Navigation (PIN) services, a focus sharpened by the 2024 launch of its dedicated RCM solution [EIN Presswire, Oct 2024]. This specialization is paired with a vertically integrated workflow that connects patient screening directly to billable activity tracking within the EHR, aiming to reduce administrative burden [Patient Discovery, retrieved 2024]. The edge is durable if the company can maintain a product lead in interpreting and automating complex, evolving Medicare rules. It is perishable if larger RCM or EHR vendors decide the oncology PIN market is large enough to justify building a competing module, or if the reimbursement rules themselves change significantly.
The company's most significant exposure is its narrow focus on oncology. While this provides depth, it limits the total addressable market and makes the business vulnerable to a downturn in specialty practice IT spending. Furthermore, it does not own the primary customer relationship; the oncology practice's EHR remains the system of record. If a major EHR vendor like Epic were to develop a native PIN and SDoH workflow module and bundle it into its core offering, Patient Discovery could be disintermediated. The company also lacks the broad community resource networks that platforms like Unite Us have built, which could be a disadvantage if practices seek a single solution for all social service referrals, not just those tied to billable oncology care.
A plausible 18-month scenario hinges on the adoption rate of the new CMS codes. If reimbursement for PIN and SDoH services accelerates as anticipated, Patient Discovery could be a winner by being the first-mover with a tuned, oncology-specific platform. It would likely capture a cohort of early-adopter cancer centers and use their case studies to expand. Conversely, if adoption is slow and practices defer investment, larger, better-capitalized horizontal platforms like Unite Us could be the loser in this niche, as they might deprioritize building deep oncology-specific billing features. However, if the market materializes quickly, those same horizontal players could also become the winner by acquiring a specialist like Patient Discovery to gain instant domain expertise.
Data Accuracy: YELLOW -- Competitive positioning is sourced from company materials; specific competitor details and market dynamics are inferred from the product's stated focus. Named competitor analysis is limited.
Opportunity
PUBLIC Patient Discovery’s opportunity hinges on converting the administrative and financial friction of managing cancer patients’ non-clinical needs into a high-margin, defensible software business.
The headline opportunity is for Patient Discovery to become the default operating system for the oncology clinic's non-clinical workflow, a role analogous to what Epic and Cerner are for clinical data. The reachable outcome is a platform that becomes embedded in the revenue cycle of community oncology practices, turning a cost center,navigating patients through social determinants of health (SDoH) and principal illness navigation (PIN) services,into a profit center. The evidence for this being reachable, not merely aspirational, is the company’s explicit alignment with new, permanent CMS reimbursement codes. The 2026 Medicare Physician Fee Schedule includes an 11% increase in payment for PIN services, a policy tailwind that directly subsidizes adoption of tools like Patient Discovery’s platform [Patient Discovery, retrieved 2024]. The company’s claim that a typical five-physician practice can generate an estimated $1.16 million in total reimbursement using its system provides a concrete, quantifiable wedge into the clinic’s budget [Patient Discovery, retrieved 2024]. This creates a clear path to becoming essential infrastructure for a financially pressured segment of healthcare.
Several concrete growth scenarios could propel the company from a niche solution to a category-defining platform.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Standard of Care in Community Oncology | Patient Discovery’s platform becomes a mandated or highly recommended component for oncology practices participating in value-based care or equity-focused payment models from major payers. | A national payer (e.g., UnitedHealth, Aetna) or a large Medicare Advantage plan formally integrates the platform’s assessment and reporting into its quality or equity reimbursement programs. | The partnership with AmerisourceBergen, a major pharmaceutical distributor with deep payer and provider relationships, demonstrates an existing channel to influence practice behavior at scale [Patient Discovery, retrieved 2024]. |
| Land-and-Expand into Adjacent Specialties | The company successfully replicates its oncology-specific workflow and reimbursement engine for other chronic, high-cost conditions like cardiology, nephrology, or neurology. | The launch of a white-labeled or condition-agnostic version of the platform, following proven success with several large oncology networks. | The core workflow,SDoH assessment, care coordination, and capturing billable services,is not unique to oncology. The technical architecture, led by CTO Julie Stern, appears designed to support multiple clinical modules [Patient Discovery, retrieved 2024]. |
What compounding looks like is a classic land-and-expand flywheel within a healthcare system. The initial win is a single clinic or small practice, where the platform demonstrates its ability to generate net-new revenue with minimal administrative lift. This proof point, such as the cited example of Nebraska Cancer Specialists billing over $30,000 in new PIN services in its first month, becomes the case study for the next sale [Patient Discovery, retrieved 2024]. As more clinics within a health system adopt the tool, the value compounds: centralized reporting gives system administrators visibility into population-level SDoH risks and reimbursement capture across their network, creating a data moat. The platform’s integration directly into the electronic medical record (EMR) without extra logins is a critical piece of this compounding effect, reducing friction for expansion across departments and locking in the workflow [Patient Discovery, retrieved 2024].
The size of the win can be framed by looking at comparable public health IT companies focused on revenue cycle management and workflow optimization. For example, Phreesia (NYSE: PHR), which provides patient intake and payment automation, reached a market capitalization of approximately $1.5 billion in 2023. While Phreesia serves a broader market, it demonstrates the valuation potential for software that sits at the intersection of patient engagement and practice revenue. If Patient Discovery executes on the "Standard of Care in Community Oncology" scenario and captures a meaningful portion of the several thousand oncology practices in the U.S., a valuation in the high hundreds of millions is a plausible outcome (scenario, not a forecast). The company’s focus on a high-reimbursement, high-complexity specialty with clear regulatory tailwinds supports a premium multiple relative to general practice management software.
Data Accuracy: YELLOW -- The core opportunity thesis is built on public CMS policy and company-provided case studies. The partnership with AmerisourceBergen is confirmed, but broader market traction and specific expansion plans are not detailed in named-publisher coverage.
Sources
PUBLIC
[Patient Discovery, retrieved 2024] Patient Discovery | https://www.patientdiscovery.com/
[EIN Presswire, Oct 2024] Patient Discovery Launches Industry-First Revenue Cycle Management Solution for SDoH, CHI, and PIN Services | https://www.patientdiscovery.com/resources/patient-discovery-partners-with-amerisourcebergen-for-cancer-care-equity
[Forbes, 2014] True Office Acquisition | https://www.forbes.com/sites/trueoffice/
[PR Newswire, 2022] Sandra Fenwick Joins Patient Discovery's Board of Directors | https://www.patientdiscovery.com/sandra-fenwick-joins-board/
[PitchBook, retrieved 2024] Patient Discovery Solutions - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/patient-discovery-solutions
[ZoomInfo, retrieved 2026] Patient Discovery Solutions Company Profile | https://www.zoominfo.com/c/patient-discovery-solutions/5852483
[LeadIQ, May 2026] Patient Discovery Company Overview | https://leadiq.com/c/patient-discovery/5a1dac832300005a00a1ce27
[ContactOut, retrieved 2026] Patient Discovery | https://www.contactout.com/patient-discovery
[The Org, retrieved 2026] Julie Stern Profile | https://theorg.com/org/patient-discovery/org-chart/julie-stern
Articles about Patient Discovery
- Patient Discovery Turns Everyday Oncology Support Into Billable Revenue — The Boston startup's platform helps cancer clinics capture CMS reimbursements for social needs and care navigation, aiming for a $1.16 million payout for a five-doctor practice.